Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and efficacy. While ischemic stroke rates were slightly higher, they were not statistically significant, warranting further phase 3 trials for confirmation.